These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16793238)

  • 21. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia.
    Fujita J; Nishida A; Sakata M; Noda T; Ito H
    Psychiatry Clin Neurosci; 2013 Jul; 67(5):345-51. PubMed ID: 23711166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients.
    Hori H; Yoshimura R; Katsuki A; Sugita AI; Atake K; Nakamura J
    J Psychiatr Res; 2013 Dec; 47(12):1843-8. PubMed ID: 24054464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study.
    Guo X; Zhai J; Wei Q; Twamley EW; Jin H; Fang M; Hu M; Zhao J;
    Neurosci Lett; 2011 Oct; 503(2):141-6. PubMed ID: 21888948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder.
    Donaldson S; Goldstein LH; Landau S; Raymont V; Frangou S
    J Clin Psychiatry; 2003 Jan; 64(1):86-93. PubMed ID: 12590629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.
    Spellmann I; Müller N; Musil R; Zill P; Douhet A; Dehning S; Cerovecki A; Bondy B; Möller HJ; Riedel M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):335-44. PubMed ID: 18347838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.
    Selva-Vera G; Balanzá-Martínez V; Salazar-Fraile J; Sánchez-Moreno J; Martinez-Aran A; Correa P; Vieta E; Tabarés-Seisdedos R
    BMC Psychiatry; 2010 Jun; 10():47. PubMed ID: 20550658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schizotypal traits and cognitive function in healthy adults.
    Noguchi H; Hori H; Kunugi H
    Psychiatry Res; 2008 Nov; 161(2):162-9. PubMed ID: 18849081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive functioning in schizophrenia with or without diabetes.
    Guo X; Zhang Z; Zhu W; Lian N; Lu H; Zhao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 36(8):724-7. PubMed ID: 21937796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
    Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
    Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia.
    Vita A; Deste G; De Peri L; Barlati S; Poli R; Cesana BM; Sacchetti E
    Schizophr Res; 2013 Oct; 150(1):51-7. PubMed ID: 23998953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schizophrenia patients using atypical medication perform better in visual tasks than patients using typical medication.
    Fernandes TP; Shaqiri A; Brand A; Nogueira RL; Herzog MH; Roinishvili M; Santos NA; Chkonia E
    Psychiatry Res; 2019 May; 275():31-38. PubMed ID: 30878854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the Northern Finland Birth Cohort 1966.
    Hulkko AP; Murray GK; Moilanen J; Haapea M; Rannikko I; Jones PB; Barnett JH; Huhtaniska S; Isohanni MK; Koponen H; Jääskeläinen E; Miettunen J
    Eur Psychiatry; 2017 Sep; 45():50-58. PubMed ID: 28728095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of medication adherence in patients with schizophrenia and bipolar disorder.
    Jónsdóttir H; Opjordsmoen S; Birkenaes AB; Simonsen C; Engh JA; Ringen PA; Vaskinn A; Friis S; Sundet K; Andreassen OA
    Acta Psychiatr Scand; 2013 Jan; 127(1):23-33. PubMed ID: 22900964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.
    Barch DM; Carter CS
    Schizophr Res; 2005 Sep; 77(1):43-58. PubMed ID: 16005384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.